Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Frequently asked questions
What sector does DFTX (DFTX) operate in?
DFTX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is DFTX (DFTX) current stock price?
As of the latest data, DFTX stock price is $46.14, with a previous close of $46.14.
What is DFTX (DFTX) current market capitalization?
DFTX market cap is approximately 6.12 billion.
What is DFTX (DFTX) Earnings Per Share (EPS)?
The trailing EPS is -$2.50, and the forward EPS is -$1.51.
What is DFTX (DFTX) EBITDA?
DFTX EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -75.22 million.
Does DFTX (DFTX) pay dividends?
No. DFTX does not pay a dividend.
What is DFTX (DFTX) beta (volatility) score?
DFTX has a beta of 2.212, indicating very high volatility compared to the market.
